Combo Therapy Beats Back Relapsed NSCLC.
Patients with EGFR-mutant non-small cell lung cancer who develop MET-driven resistance to an EGFR inhibitor-be it a first-, second-, or third-generation drug-stand to benefit from follow-up treatment with a combination of EGFR-targeted osimertinib and MET-blocking savolitinib, according to an interim analysis of two expansion cohorts from the multiarm TATTON trial.